Patents by Inventor Christine I. Wooddell
Christine I. Wooddell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141351Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.Type: ApplicationFiled: December 6, 2023Publication date: May 2, 2024Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
-
Patent number: 11884920Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.Type: GrantFiled: November 10, 2021Date of Patent: January 30, 2024Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
-
Publication number: 20230355654Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: ApplicationFiled: December 21, 2022Publication date: November 9, 2023Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. WOODDELL, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
-
Publication number: 20230355651Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: December 2, 2022Publication date: November 9, 2023Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
-
Patent number: 11590156Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: GrantFiled: August 11, 2020Date of Patent: February 28, 2023Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
-
Publication number: 20230002768Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.Type: ApplicationFiled: June 8, 2022Publication date: January 5, 2023Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. Wooddell, David L. Lewis, Darren H. Wakefield, Lauren Almeida, Steven B. Kanner
-
Patent number: 11534453Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: GrantFiled: September 9, 2020Date of Patent: December 27, 2022Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
-
Patent number: 11517584Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: GrantFiled: November 17, 2021Date of Patent: December 6, 2022Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
-
Patent number: 11384355Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.Type: GrantFiled: May 31, 2019Date of Patent: July 12, 2022Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I Wooddell, David L Lewis, Darren H Wakefield, Lauren Almeida, Steven B Kanner
-
Publication number: 20220170015Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.Type: ApplicationFiled: November 10, 2021Publication date: June 2, 2022Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
-
Publication number: 20220079973Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: November 17, 2021Publication date: March 17, 2022Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
-
Patent number: 11203756Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.Type: GrantFiled: September 12, 2019Date of Patent: December 21, 2021Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
-
Publication number: 20210100829Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: August 11, 2020Publication date: April 8, 2021Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
-
Publication number: 20210052624Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: ApplicationFiled: September 9, 2020Publication date: February 25, 2021Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. WOODDELL, David B. ROZEMA, David L. LEWIS, Darren H. WAKEFIELD, Lauren J. ALMEIDA
-
Patent number: 10806750Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: GrantFiled: October 1, 2018Date of Patent: October 20, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
-
Publication number: 20200208149Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.Type: ApplicationFiled: September 12, 2019Publication date: July 2, 2020Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
-
Patent number: 10450565Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.Type: GrantFiled: January 10, 2018Date of Patent: October 22, 2019Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
-
Publication number: 20190284558Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.Type: ApplicationFiled: May 31, 2019Publication date: September 19, 2019Inventors: Christine I Wooddell, David L Lewis, Darren H Wakefield, Lauren Almeida, Steven B Kanner
-
Publication number: 20190255091Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: February 4, 2019Publication date: August 22, 2019Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
-
Publication number: 20190071670Abstract: The application relates to methods of treatment and treatment regimens for Alpha-1 Antitrypsin deficiency (AATD) and the conditions, manifestations, and diseases caused by AATD, by the administration of one or more expression-inhibiting oligomeric compounds having a nucleobase sequence complementary to a coding sequence in the Alpha-1 Antitrypsin (A1AT or AAT) gene that inhibits the expression of the AAT gene, in combination with one or more autophagy enhancing agents that enhance and/or induce the endogenous autophagy mechanism to facilitate and encourage clearance of polymerized mutant AAT protein accumulated in the endoplasmic reticulum of hepatocytes.Type: ApplicationFiled: August 9, 2018Publication date: March 7, 2019Inventors: Christine I. Wooddell, Ryan M. Peterson, Peter B. Leone